Characteristics
| |
All patients
|
---|
N
| |
30
|
Age, years
| |
65.5 ± 7.7
|
Sex, male
|
n (%)
|
23 (76.7)
|
Duration of hemodialysis
|
years
|
15.4 ± 10.5
|
Etiology of end-stage renal disease
|
n (%)
| |
Diabetic nephropathy
| |
13 (43.3)
|
Polycystic kidney disease
| |
2 (6.7)
|
Interstitial nephritis
| |
3 (10.0)
|
Glomerulonephritis
| |
7 (23.3)
|
Others
| |
5 (16.7)
|
Weight
|
kg
|
51.2 ± 10.1
|
Previous treatment
|
n (%)
| |
Naïve
| |
21 (70.0)
|
Relapse
| |
5 (16.6)
|
Non-viral response
| |
4 (13.3)
|
Liver cirrhosis
|
n (%)
|
9 (30.0)
|
Serum HCV-RNA levels
|
log10IU/mL
|
5.15 ± 0.95
|
NS5A inhibitor RAVs
|
n (%)
|
2 (6.7)
|
Laboratory data
|
Hemoglobin
|
g/dL
|
10.6 ± 1.50
|
WBC
|
/μL
|
5484 ± 1760
|
Neutrophils
|
/μL
|
3718 ± 1381
|
Platelets
|
×104/μL
|
16.5 ± 6.38
|
Serum AST
|
IU/L
|
20.1 ± 13.1
|
Serum ALT
|
IU/L
|
16.1 ± 8.21
|
Serum albumin
|
g/dL
|
3.40 ± 0.35
|
BUN
|
mg/dL
|
51.9 ± 16.5
|
Serum creatinine
|
mg/dL
|
9.31 ± 2.39
|
Serum total bilirubin
|
mg/dL
|
0.36 ± 0.16
|
Alpha-fetoprotein
|
ng/mL
|
2.39 ± 0.98
|
- Data are expressed as median, number (%), or mean ± standard deviation
-
RAVs resistance-associated variants, BUN blood urea nitrogen, PT-INR international normalized ratio of prothrombin time